InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,244.80
(
0.27%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.11
(
-0.41%
)
Bitcoin
69,849.97
(
-0.40%
)
Post# of 549
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Blade$dream

Send PM Follow Ignore
Followers 151
Posts 13623
Boards Moderated 0
Alias Born 02/21/2010

Blade$dream

Re: Blade$dream post# 338

Thursday, 11/09/2017 4:44:52 AM

Thursday, November 09, 2017 4:44:52 AM

Post# of 549
$OTIC Anticipated Upcoming Milestones:

Meet with the FDA during the first quarter of 2018 to review the AVERTS Phase 3 clinical trial data and discuss clinical requirements for OTIVIDEX registration in patients with Ménière’s disease.

Complete the pipeline review and prioritization, and present a development plan for multiple clinical and preclinical programs in the first quarter of 2018.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up